Research & Analysis
Scientific, economic, and regulatory barriers have led many major pharmaceutical companies to limit or stop investing in antibiotic innovation, just as the rise of resistant “superbugs” makes it more important than ever to develop novel antimicrobial drugs. The world needs new, targeted scientific research and innovative policies to revitalize the drug pipeline, produce new... Read More
In December, President Barack Obama signed into law the 21st Century Cures Act, which includes several provisions that will play an important role in combating the growing global threat of antibiotic resistance. Read More
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has recently announced a new funding opportunity for milestone-driven research aimed at advancing the discovery of urgently needed antibiotics by systematically tackling key scientific questions. Read More
Support our Work
Invest with Pew to combat antibiotic resistance.